- Home
- IDYA vs CGON Comparison
IDYA vs CGON Comparison
Compare IDYA & CGON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IDYA
- CGON
- Stock Information
- Founded
- IDYA 2015
- CGON 2010
- Country
- IDYA United States
- CGON United States
- Employees
- IDYA N/A
- CGON N/A
- Industry
- IDYA Biotechnology: Pharmaceutical Preparations
- CGON
- Sector
- IDYA Health Care
- CGON
- Exchange
- IDYA Nasdaq
- CGON NYSE
- Market Cap
- IDYA 2.2B
- CGON 2.3B
- IPO Year
- IDYA 2019
- CGON 2024
- Fundamental
- Price
- IDYA $22.18
- CGON $29.08
- Analyst Decision
- IDYA Strong Buy
- CGON Strong Buy
- Analyst Count
- IDYA 13
- CGON 10
- Target Price
- IDYA $53.67
- CGON $65.11
- AVG Volume (30 Days)
- IDYA 890.0K
- CGON 809.2K
- Earning Date
- IDYA 02-18-2025
- CGON 02-02-2025
- Dividend Yield
- IDYA N/A
- CGON N/A
- EPS Growth
- IDYA N/A
- CGON N/A
- EPS
- IDYA N/A
- CGON N/A
- Revenue
- IDYA $3,922,000.00
- CGON $684,000.00
- Revenue This Year
- IDYA N/A
- CGON $210.00
- Revenue Next Year
- IDYA $251.89
- CGON N/A
- P/E Ratio
- IDYA N/A
- CGON N/A
- Revenue Growth
- IDYA N/A
- CGON 258.12
- 52 Week Low
- IDYA $22.10
- CGON $25.77
- 52 Week High
- IDYA $47.74
- CGON $50.23
- Technical
- Relative Strength Index (RSI)
- IDYA 31.90
- CGON 44.86
- Support Level
- IDYA $22.17
- CGON $27.70
- Resistance Level
- IDYA $24.06
- CGON $29.69
- Average True Range (ATR)
- IDYA 1.06
- CGON 1.43
- MACD
- IDYA -0.22
- CGON 0.16
- Stochastic Oscillator
- IDYA 1.84
- CGON 31.29
About IDYA IDEAYA Biosciences Inc.
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. It is engaged in applying capabilities across multiple classes of precision medicine, including direct targeting of oncogenic pathways and synthetic lethality. The company's product candidate IDE196 is a protein kinase C, or PKC, an inhibitor for genetically defined cancers having GNAQ or GNA11 gene mutations.
About CGON CG ONCOLOGY INC
CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. The company's lead candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.